Clinical Trial

A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Study acronym: OBSAPA
Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior of metastatic hormone-sensitive prostate cancer (mHSPC) participants treated with apalutamide during the first year of continued treatment.
Protocol Amendment History 2 changes
notable Enrollment increased: 270 -> 540 participants 2026-07-07
minor Completion pushed: 2028-01-03 -> 2028-09-18 2026-07-07
Trial Details
NCT Number NCT07451002
Lead Sponsor Janssen Cilag S.A.S.
Conditions Prostatic Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
Enrollment 540 participants
Start Date 2025-12-18
Primary Completion 2028-01-03 (estimated)
Study Completion 2028-09-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-06